← Leaderboards
Navneet Kaur Dhillon
University Of Kansas Medical Center
$8,934,291
Attributed
$8,934,291
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,934,291 · 7
By mechanism
R01$8,014,479 · 4
R56$488,562 · 1
R03$431,250 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- Alexey Ladokhin$2,706,980
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationMediatingHiv-1CardiopulmonaryBlood VesselsVascular DiseasesTherapeutic InterventionLungDrug AbuseIntravenous Drug UserDrug Of AbuseReportingPulmonary Arterial HypertensionBaseCocaineVascular RemodelingPathogenesisLinkIn VivoViral ProteinsPulmonary HypertensionSmooth Muscle MyocytesAntiretroviral TherapyProteins
Grant awards (23)
Drug abuse and HIV-associated pulmonary vascular injury$590,415
R01 · FY2024 · HL · contact PI
Drug abuse and HIV-associated pulmonary vascular injury$602,416
R01 · FY2023 · HL · contact PI
Drug abuse and HIV-associated pulmonary vascular injury$302,137
R01 · FY2023 · HL · contact PI
Drug abuse and HIV-associated pulmonary vascular injury$600,466
R01 · FY2022 · HL · contact PI
Drug abuse and HIV-associated pulmonary vascular injury$689,513
R01 · FY2021 · HL · contact PI
Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction$473,740
R01 · FY2020 · DA · contact PI
Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction$473,740
R01 · FY2019 · DA · contact PI
Impact of Opiate abuse on HIV-mediated Pulmonary Vascular Remodeling$509,422
R01 · FY2018 · HL · contact PI
Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction$478,878
R01 · FY2018 · DA · contact PI
Impact of Opiate abuse on HIV-mediated Pulmonary Vascular Remodeling$510,638
R01 · FY2017 · HL · contact PI
Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction$367,316
R01 · FY2017 · DA · contact PI
Impact of Opiate abuse on HIV-mediated Pulmonary Vascular Remodeling$513,994
R01 · FY2016 · HL · contact PI
Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction$411,434
R01 · FY2016 · DA · contact PI
HIV/Cocaine mediated human pulmonary vascular remodeling: Role of BMPR signaling.$298,980
R01 · FY2016 · DA · contact PI
Impact of Opiate abuse on HIV-mediated Pulmonary Vascular Remodeling$488,562
R56 · FY2015 · HL · contact PI
HIV/Cocaine mediated human pulmonary vascular remodeling: Role of BMPR signaling.$297,470
R01 · FY2015 · DA · contact PI
HIV/Cocaine mediated human pulmonary vascular remodeling: Role of BMPR signaling.$302,000
R01 · FY2014 · DA · contact PI
HIV/Cocaine mediated human pulmonary vascular remodeling: Role of BMPR signaling.$289,920
R01 · FY2013 · DA · contact PI
HIV/Cocaine mediated human pulmonary vascular remodeling: Role of BMPR signaling.$302,000
R01 · FY2012 · DA · contact PI
PDGF-Receptor regulation in Cocaine and Tat mediated Smooth Muscle Hyperplasia$141,000
R03 · FY2012 · DA · contact PI
PDGF-Receptor regulation in Cocaine and Tat mediated Smooth Muscle Hyperplasia$141,000
R03 · FY2011 · DA · contact PI
Oral Delivery of Nanoparticles encapsulated with HIV-DNA Vaccine$74,250
R03 · FY2010 · AI · contact PI
Oral Delivery of Nanoparticles encapsulated with HIV-DNA Vaccine$75,000
R03 · FY2009 · AI · contact PI